Steve Schonfeld’s Cognition Therapeutics CGTX Stock Holding History

Steve Schonfeld’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$7.59K	–	2659
2026 Q1	$7.59K	Buy	+10,000	New	+$11.6K	﹤0.01%	2106

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Steve Schonfeld's CGTX Position: Q2 2026 in Review

Steve Schonfeld sold out of Cognition Therapeutics (CGTX) in Q2 2026, closing a stake of 10,000 shares — an estimated $7.59K sold.

Steve Schonfeld first reported a position in CGTX in Q1 2026 and held it in 1 quarter. The position peaked at $7.59K in Q1 2026. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Steve Schonfeld reported no remaining Cognition Therapeutics position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 10,000 Cognition Therapeutics shares in Q2 2026, an estimated $7.59K.
Steve Schonfeld first reported a position in Cognition Therapeutics in Q1 2026 and held it in 1 quarter.
Steve Schonfeld's Cognition Therapeutics position peaked at $7.59K in Q1 2026.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.